Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices 8213 

Fishers Lane, Room 3G31B, Rockville, MD 

20852, (240) 669–5060, james.snyder@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 27, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–02302 Filed 2–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; Rare Diseases. 

Date: February 18, 2021. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1076, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Carol Lambert, Ph.D., 

Office of Scientific Review, National Center 

for Advancing Translational Sciences, 

National Institutes of Health, 6701 

Democracy Boulevard, Room 1076, Bethesda, 

MD 20892, 301–435–0814, lambert@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: January 22, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–02274 Filed 2–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Resource Related 

Research Projects (R24 Clinical Trial Not 

Allowed). 

Date: February 23, 2021. 

Time: 10:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G20, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Zhuqing (Charlie) Li, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G20, 

Rockville, MD 20852, (240) 669–5068, 

zhuqing.li@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 26, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–02275 Filed 2–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing as a biological material to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Jeffrey Thruston at 301–594–5179 or 

jeffrey.thruston@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

A VSV–EBOV-Based Vaccine Against 

COVID–19 

Description of Technology 

Severe acute respiratory syndrome 

coronavirus 2 (SARS–CoV–2) is the 

causative agent of for coronavirus 

disease 2019 (COVID–19). COVID–19 is 

characterized by fever, cough, difficulty 

breathing, loss of taste and smell, 

nausea, and sore throat. As of the fourth 

quarter 2020, COVID–19 is responsible 

for over 1.17 million deaths worldwide. 

As the pandemic continues to surge, the 

importance of a safe, affordable, and 

efficacious vaccine is of urgent 

importance. The present technology 

utilizes the well characterized vesicular 

stomatitis virus (VSV) encoding the 

Ebola virus (VSV–EBOV) to express 

additionally a codon-optimized SARS– 

CoV–2 spike protein. A single intranasal 

or intramuscular administration of the 

vaccine showed protective efficacy 

against COVID–19 in hamsters after 4 

weeks. A single intramuscular injection 

showed protective efficacy against 

COVID–19 pneumonia in rhesus 

macaques within 10 days. The vaccine 

is inexpensive to replicate, elicits a high 

antigen-specific antibody titer within 


jbell on DSKJLSW7X2PROD with NOTICES